China Pharma Holdings Inc. Announces 1-for-10 Reverse Stock Split
China Pharma Holdings Inc. (NYSE American: CPHI) announced a 1-for-10 reverse stock split effective March 6, 2023. This decision was approved unanimously by the Board of Directors and stockholders at the Annual Meeting held on December 27, 2022. Following the split, the new CUSIP number for common stock will be 16941T-203. Each stockholder's percentage interest will remain unchanged, although fractional shares will be rounded up to the nearest whole share. China Pharma specializes in pharmaceuticals targeting high-incidence diseases in China, and maintains a broad distribution network across the country.
- The reverse stock split is expected to improve the company's stock price and market perception.
- Approval of the split indicates board confidence in the company's future.
- Maintaining a stable distribution network across China enhances operational prospects.
- Reverse stock splits can sometimes indicate underlying financial issues or declining stock performance.
The reverse stock split at a ratio of 1-for-10 shares was approved by the Company's Board of Directors through unanimous written consent and the Company's stockholders through Annual Meeting for the fiscal year ended on
Upon the effectiveness of the reverse stock split, every 10 shares of the Company's issued and outstanding common stock will automatically be converted into one share of issued and outstanding common stock. No fractional shares will be issued as a result of the reverse stock split. Instead, any fractional shares that would have resulted from the split will be rounded up to the next whole number. The reverse stock split affects all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's outstanding common stock, except for adjustments that may result from the treatment of fractional shares.
About
Safe Harbor Statement
Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties may include, but are not limited to: the achievability of financial guidance; success of new product development; unanticipated changes in product demand; increased competition; downturns in the Chinese economy; uncompetitive levels of research and development; and other information detailed from time to time in the Company's filings and future filings with the
View original content:https://www.prnewswire.com/news-releases/china-pharma-holdings-inc-announces-1-for-10-reverse-stock-split-301755166.html
SOURCE
FAQ
What is the effective date of China Pharma's reverse stock split?
What is the ratio of China Pharma's reverse stock split?
Will shareholders retain their percentage interest after the split?
What is the new CUSIP number after the reverse stock split for CPHI?